Skip to content
中文EN

Oncology

Tumor biology and anticancer therapy: from mechanism papers to pivotal readouts and launches.

673 picksRelatedImmunotherapyTumor microenvironmentADCs & conjugates

Latest picks

21–40 of 673
Oct 19Mon
  1. WeChat72

    Guangzhou Laboratory Finds SOX2 Condensates Drive Chemo Resistance in Lung Squamous Cancer, Designs Peptide Hx1R8

    Hongjie Yao's group at Guangzhou National Laboratory reports in Signal Transduction and Targeted Therapy that a prion-like domain (PrLD) in SOX2 drives liquid-liquid phase separation to form condensates. These condensates directly bind and sequester chemotherapy drugs and weaken the DNA damage response, producing broad chemotherapeutic resistance in lung squamous cell carcinoma (LSCC).

    Why it matters: The paper pairs mechanistic evidence of SOX2 condensates sequestering chemotherapy drugs with in vivo tumor-suppression data for Hx1R8 plus cisplatin.

  2. WeChat62

    SPIC Isotope Venture in Chongqing Becomes First Chinese Firm Licensed for Bulk Actinium-225

    State Power Investment Corporation isotope unit Hexin Sotone? No: SPIC Nuclear Isotope Tongchuang (Chongqing) Technology has obtained a Grade A non-sealed radiation safety license issued by China's Ministry of Ecology and Environment, becoming the first company in China qualified to produce, sell and use actinium-225 at scale. The project is equipped with two proton cyclotrons (120 MeV and 50 MeV) with a Phase I investment of 918 million yuan; once fully operational it is expected to add up to 188 curies of annual actinium-225 capacity. Actinium-225 is a key raw material for alpha-targeted therapy of advanced tumors; current global supply does not exceed 8 curies and has long been dominated by foreign producers.

    Why it matters: First Chinese company licensed for commercial-scale actinium-225 production, sale and use.

  3. WeChat65

    Li Feng Team Shows PAK4 Kinase Promotes Exosome Release to Deepen Melanoma Immunosuppression

    A team led by Feng Li at China Medical University, with Ruizhi Zhou as first author, reports in PNAS that PAK4 kinase intensifies melanoma immunosuppression through a dual mechanism that boosts exosome secretion. It phosphorylates ANXA2 at Ser26 in a kinase activity-dependent manner to promote multivesicular body docking, and retains TRIM21 in the nucleus independently of kinase activity, stabilizing SYT1 to support SNARE complex assembly and membrane fusion.

    Why it matters: The paper defines kinase-dependent and kinase-independent mechanisms by which PAK4 drives exosome release, supporting combining PAK4 inhibitors with immune checkpoint blockade.

  4. YouTube82

    Monika Wolkers Lecture: Translational Control of CD8 T Cells and SONAR Machine-Learning Engineering

    Global ImmunoTalks aired an expert lecture by Monika Wolkers of the Sanquin Research Institute, arguing that protein abundance in CD8 T cells is driven mainly by translational regulation, and presenting SONAR, her team's machine-learning model for predicting protein abundance.

    Why it matters: SONAR integrates multiple UTR features to predict protein abundance and engineers 3'UTRs to raise TCR expression, and the method transfers to other protein engineering settings.

  5. YouTube62

    Macrophage Subsets and T Cell Immunity in Breast Tumors: A Talk by Julie Helft

    Julie Helft used markers including FOLR2 to classify tumor-associated macrophages (TAMs) in breast tumors into two groups, finding that FOLR2+ TAMs localize to tumor nests and can prime naive CD8+ T cells in vitro. Tumors rich in FOLR2+ TAMs are hot tumors, with FOLR2+ TAMs co-localizing with CD8+ T cells in perivascular lymphoid aggregates. In tumor-bearing mice, the bone marrow niches of hematopoietic stem cells and mesenchymal stem cells are reprogrammed toward a promyeloid direction.

    Why it matters: Classifying TAMs by FOLR2 in breast tumors and showing the FOLR2+ subset primes CD8+ T cells in situ provides a citable cellular reference for macrophage subset-based immunotherapy.

Oct 18Sun
  1. Medical Xpress56

    Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients

    The LIFT trial from UNC Lineberger enrolled 179 adult cancer patients at 8 oncology clinics in North Carolina, 4 rural and 4 nonrural. After financial navigation, FACIT-COST financial toxicity scores improved by an average of 8.1 points on a 44-point scale, with gains in quality-of-life measures including depression and anxiety.

    Why it matters: The brief gives FACIT-COST score improvement across 8 sites and 179 patients plus depression and anxiety endpoints, letting readers assess replicating the model at their own institutions.

  2. Cell73

    CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer.

    Single-cell CRISPR screens in the aged tumor microenvironment identified Dusp5 and Zfp219 as two key regulators driving CD8+ T cell dysfunction (DOI: 10.1016/j.cell.2026.07.016).

    Why it matters: Single-cell CRISPR screens in aged tumors found Dusp5 and Zfp219 as targets driving CD8+ T cell dysfunction; human ZNF219 correlates with worse immunotherapy survival in older patients.

  4. 顶刊论文（社媒热度）67

    Therapeutic-scale CAR-NK microrobots with programmable swarm navigation for targeted solid tumor therapy.

    The study engineers CAR-NK cells into magnetic biohybrid microrobots that achieve controllable long-distance targeted navigation at therapeutic doses guided by external magnetic fields in mice and nonhuman primates. Different magnetic field inputs switch the microrobot swarm between vortex and ribbon modes, for dense aggregation during targeted navigation and broad dispersion for wide coverage. Delivered by intrathecal injection, the platform achieved proof-of-concept treatment of metastatic leptomeningeal carcinomatosis in the cerebrospinal fluid of nonhuman primates, with navigation visualized in real time by angiography. DOI: 10.1126/sciadv.aef9412.

    Why it matters: The paper demonstrates proof of concept for CAR-NK microrobot swarm navigation in mice and nonhuman primates as a methodological reference for cell therapy delivery to solid tumors.

  5. 文献与产业新闻36

    Development and Validation of a Stability-Indicating UPLC-PDA Method for Fruquintinib: LC-QTOF-MS/MS-Based Structural Characterization of Degradation Products and In Silico ADMET Prediction

    Researchers subjected fruquintinib to acid, base, oxidative and other forced degradation conditions per ICH Q1A(R2) and developed and validated a stability-indicating UPLC-PDA method. Under acid, base and oxidative stress, two common degradation products were detected, DP-1 (m/z 207.0756) and DP-2 (m/z 221.0900); DP-2 is reported for the first time.

    Why it matters: A validated stability-indicating UPLC-PDA method and a first-reported degradation product.

  6. YouTube52

    Expert Analysis: SUPREMO Trial 5-Year Patient-Reported Outcomes After Mastectomy Radiotherapy

    Five-year patient-reported outcomes from the SUPREMO trial in 947 UK women show no detectable differences between chest-wall radiotherapy and control groups on most measures; only chest-wall symptom scores reached the threshold for meaningful difference (12 vs 9.9, difference threshold 8.8). A subgroup suggests women who had two axillary procedures (sentinel biopsy plus dissection) had chest-wall symptoms worsen more than 2.5-fold with radiotherapy, with no extra effect after one procedure; the authors call this a potential effect, as the subgroup was not powered. The video frames these as substantive data to help patients weigh radiotherapy, not as a recommendation.

    Why it matters: The article gives chest-wall symptom scores and axillary-surgery subgroup differences patients can use when weighing radiotherapy.

Oct 17Sat
  1. BioCentury76

    EMA’s CHMP backs RevMed’s first-in-class pancreatic cancer therapy

    At its October meeting, EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Revolution Medicines' Rasonque (daraxonrasib) for patients with metastatic pancreatic ductal adenocarcinoma who have received at least one prior line of therapy.

    Why it matters: The CHMP opinion specifies the indication and number of prior therapy lines, enabling comparison on the same timeline with FDA voucher-approved drugs.

  2. Medical Xpress54

    DNA sequencing reveals how rare cancer spread between twins before birth

    Barbara Walkowiak and colleagues report in Nature Communications that deep whole-genome sequencing and RNA sequencing of a pair of identical twins and their placental tissue shows the MN1::ZNF341-driven undifferentiated sarcoma in Twin A and Twin B both originated from a facial tumor in Twin A in early pregnancy. Cancer cells transferred to Twin B once, via the placenta, in late pregnancy, accompanied by a large-scale exchange of blood cells.

    Why it matters: Whole-genome sequencing and DNA lineage tracing of rare prenatal cancer transmission infer when the identical twins' embryo split, offering a transferable method for reconstructing early embryonic development.

  3. Medical Xpress55

    Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer

    In the Phase Ib FURTHER trial of 60 patients with EGFR PACC-mutated non-small cell lung cancer, median progression-free survival was 11.1 months with firmonertinib 160 mg daily and 16 months with 240 mg daily. In previously untreated patients, objective response rates were 43% and 68%, respectively; 80% of evaluable patients achieved complete ctDNA clearance, and among 17 patients with brain metastases, 47% had brain tumor shrinkage and 41% achieved complete response.

    Why it matters: Reports progression-free survival and objective response rates for firmonertinib and supports structure-guided targeted therapy selection, prompting the Phase III ALPACCA head-to-head trial.

  4. Medical Xpress52

    Study finds common chemicals may alter normal breast development

    A team led by Tufts University researchers, publishing in PNAS, tested chemicals at low concentrations close to real human exposure using breast organoids from 13 healthy women. Combined exposure to three bisphenols, BPA, BPS and BPF, disrupted normal breast development and triggered molecular changes in organoids from most donors. Comparison with human breast cancer data showed the molecular signature was most enriched in samples from patients with invasive lobular carcinoma, but the paper explicitly states this result does not constitute direct evidence that the chemicals cause cancer. DOI: 10.1073/pnas.2613054123.

    Why it matters: Organoids from 13 healthy women tested bisphenol mixtures at near-realistic human exposure concentrations, providing human in vitro evidence distinct from animal models and high-dose toxicology.

  5. Medical Xpress64

    Fueling growth, blinding immunity: The two-way amino acid trap inside tumors

    Medical Xpress reports that a team led by Weiwei Yu at Zhejiang University published a study in Science Immunology showing that tumors drive both proliferation and immune evasion simultaneously through a trade-off in arginine and lysine metabolism.

    Why it matters: Links the arginine-lysine metabolic trade-off to immune checkpoint therapy response, with clinical and mouse data supporting a metabolism-based combination therapy hypothesis.

  6. Medical Xpress47

    Molecular imaging demonstrates promise for predicting complete pathologic response in HER2-positive breast cancer

    68Ga-HER2 PET/CT can predict pathologic complete response (pCR) in HER2-positive breast cancer after just two cycles of neoadjuvant therapy: patients with a decline of at least 61% in primary lesion uptake had a pCR rate of 85%, versus 38% for those with a smaller decline. The prospective study enrolled 44 biopsy-confirmed patients; baseline scans could not distinguish pCR from non-pCR. The authors note limitations including small sample size, single center, and heterogeneous treatment regimens, requiring further validation.

    Why it matters: Early imaging-based prediction of treatment response is relevant to clinicians and industry.

  7. Medical Xpress56

    Genomic cancer driver study reveals new clues to why some prostate cancers become aggressive

    A joint team from OICR and the University of Copenhagen published a study in Nature Communications analyzing whole-genome sequencing data from nearly 1,000 prostate cancer samples. They found that 97% of tumors carried at least one known or potential cancer driver alteration, and identified four genomic subtypes associated with increased metastatic risk. The researchers also uncovered chromosomal rearrangements involving enhancers of solute carrier genes in non-coding regions, and observed differences in driver alterations across ancestral groups.

    Why it matters: The study identifies non-coding driver alterations and four metastasis-associated subtypes in whole-genome data from nearly 1,000 prostate cancers, providing a reference map for mechanism research and stratified treatment.

  8. Nature73

    Divergent genomic evolution in astrocytomas and oligodendrogliomas.

    Longitudinal whole-genome and whole-exome sequencing of tumors from 183 patients with IDH-mutant glioma shows astrocytomas and oligodendrogliomas follow divergent evolutionary paths. Recurrent oligodendrogliomas acquired PI3K and NOTCH1 mutations with higher mutational burden, while recurrent astrocytomas gained oncogene amplifications and CDKN2A/B homozygous deletions alongside chromosomal instability. In both, convergent acquired alterations tracked with worse outcomes, implying selection of treatment-refractory clones.

    Why it matters: Defines genetically distinct evolutionary routes that may explain differential treatment response in IDH-mutant gliomas.

  9. YouTube71

    Fc receptor engagement lets anti-CD25 antibodies deplete intratumoral Tregs, experts explain

    Experts on ImmuneZoom discuss how anti-CD25 antibodies deplete intratumoral Tregs through Fc receptor mechanisms. A non-IL-2-blocking CD25 antibody (NIB) achieved 100% complete regression as a single agent in inflamed tumors, and in a glioblastoma model, combined with an anti-EGFRv3 antibody, also reached 100% complete regression via IL-2-driven CD8 expansion and IFN-gamma activation of macrophages. The humanized anti-CD25 RG6292 depleted Tregs in blood and was well tolerated but achieved under 2-fold, unstable intratumoral depletion, which may explain clinical failure; the team now studies boosting Fc receptor activity in the tumor microenvironment.

    Why it matters: Expert analysis of why Fc-mediated intratumoral Treg depletion determines anti-CD25 antibody efficacy in cancer.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org